Russell Szmulewitz to Lutetium
This is a "connection" page, showing publications Russell Szmulewitz has written about Lutetium.
Connection Strength
0.244
-
[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial. Lancet. 2026 Aug 29; 408(10557):793-807.
Score: 0.244